Format

Send to

Choose Destination
Biochem Biophys Res Commun. 2018 Jan 1;495(1):700-705. doi: 10.1016/j.bbrc.2017.11.003. Epub 2017 Nov 3.

Generation of rationally-designed nerve growth factor (NGF) variants with receptor specificity.

Author information

1
Apoptosis Research Centre, NUI, Galway, Ireland.
2
EMBL/CRG Systems Biology Research Unit, Centre for Genomic Regulation, Barcelona, Spain; Institute for Research in Immunology and Cancer, University of Montréal, Montreal, QC, Canada.
3
EMBL/CRG Systems Biology Research Unit, Centre for Genomic Regulation, Barcelona, Spain; Universitat Pompeu Fabra, 08003 Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats, Pg. Lluís Companys 23, 08010 Barcelona, Spain.
4
Apoptosis Research Centre, NUI, Galway, Ireland. Electronic address: Adrienne.gorman@nuigalway.ie.

Abstract

Nerve growth factor (NGF) is the prototypic member of the neurotrophin family and binds two receptors, TrkA and the 75 kDa neurotrophin receptor (p75NTR), through which diverse and sometimes opposing effects are mediated. Using the FoldX protein design algorithm, we generated eight NGF variants with different point mutations predicted to have altered binding to TrkA or p75NTR. Of these, the I31R NGF variant exhibited specific binding to p75NTR. The generation of this NGF variant with selective affinity for p75NTR can be used to enhance understanding of neurotrophin receptor imbalance in diseases and identifies a key targetable residue for the development of small molecules to disrupt binding of NGF to TrkA with potential uses in chronic pain.

KEYWORDS:

FoldX; NGF; TrkA; p75 neurotrophin receptor (p75(NTR))

PMID:
29108999
DOI:
10.1016/j.bbrc.2017.11.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center